Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-404calvasiranHyperlipidemiaCardiometabolic · RNA
Outcomes study fully enrolled
CLV-412lorvatideObesityCardiometabolic · Peptide
Phase 3 readout H2 2027
CLV-419Heart failure (HFpEF)Cardiometabolic · Antibody
Phase 2 enrollment ongoing
CLV-427Lp(a) elevationCardiometabolic · RNA
Single ascending dose complete
Pipeline as of September 30, 2026. Programs and data are fictional.